News

Do you want to help support student interns? Apply Now!

As students have shown great interest in the upcoming STEM2VA Summer Internship Program, we at VA Bio-Connect want to continue to invite employers to register as host sites for this great opportunity in providing experiential learning to those interested in the life sciences. With an application close date of Jan 31, 2022. There were over 1000 students interested, with over 350 submissions by the closing date. Students have shown interest in all regions across the Commonwealth of Virginia, with specific student interests in bioengineering (180), medical devices (194), and pharmaceuticals (210) respectively.

 

Currently, over 25 employers including; Atelerix Life Sciences Inc. (Charlottesville/Albemarle), ReAlta Life Sciences and LifeNet Health (Coastal VA), Athari Bio Sciences, Inc. and Polaris Genomics (Northern VA), Tympanogen (Richmond), CytoRecovery (Roanoke), and many others across Virginia have registered to host student interns. Employers are encouraged to register as application reviews have just begun and will continue to mid-March to ensure student award letters are presented to the 100 candidates by March 31, 2022. This extraordinary experience is great for the next generation of life science professionals. If you are interested in hosting a student intern, please register here to receive your link to begin reviewing applications.

Any questions you have before registering, please contact VA Bio-Connect Admin at vbcintern@vabio.org for assistance. We look forward to matching you with qualified candidates.

Recent News

04/02/2025

VCU startup wins $800k grant to propel its infection-fighting surgical gel

With an innovation that could advance brain and spinal surgeries, a Virginia Commonwealth University startup has received an $800,000 state grant to support development of its infection-fighting gel. Pascal Medical Corp. is one of four grant recipients to receive awards from Virginia Catalyst, a nonprofit created by the General Assembly and funded by the state’s general

04/02/2025

Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases, today announces additional highly positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome (NS) study. After 6 weeks of continued whole body application

04/02/2025

Charlottesville Angel Network Celebrates 10 Years, Surpasses $20 Million in Investments

The Charlottesville Angel Network (CAN), a group of accredited investors dedicated to supporting early-stage ventures, proudly marks its 10th anniversary this month. Since its inception, CAN angel investor members have invested more than $20 million in nearly 80 startups, fostering innovation both locally and beyond. Reflecting on a decade of achievements, CAN has realized returns